Evaluation of New FIGO Staging System for Endometrial Stromal Sarcoma of the Uterus = Evaluation of New FIGO Staging System for Endometrial Stromal Sarcoma of the Uterus

다국어 초록 (Multilingual Abstract)

The aim of this study is to detect differences in overall survival between the 1988 FIGO staging and revised 2008 FIGO staging of uterine endometrial stromal sarcoma. The aim of this study is to detect differences in overall survival between the 1988 FIGO staging and revised 2008 FIGO staging of uterine endometrial stromal sarcoma. Of 109 patients with LGESS, 86 patients (78.9%) had stage I disease, 5 patients (4.6%) had stage II disease, 9 patients (8.3%) were diagnosed as stage III, and 9 patients (8.3%) had stage IV disease by 1988 FIGO staging system. According to revised 2008 FIGO staging system, 8 patients (7.3%) were downstaged; 3 patients were downstaged from stage II to I and 5 patients were downstaged from stage III to II respectively. The difference in median survival of 4 stages (I-IV) was statistically significant using both staging system (1998 vs. 2008 FIGO staging system, p=0.006 vs. p=0.013). Comparing the median survival of 2 subgroups, both staging system had significant difference but previous staging system had more accurate discriminability (1998 vs. 2008, p=0.006 vs. p=0.019, HR 5.470 vs.4.286). Based upon our analysis of 109 patients with uterine LGESS, the revised FIGO staging system was appropriate to predict survival.